Literature DB >> 7518965

Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF).

S Endo1, K Inada, T Kasai, T Takakuwa, H Nakae, M Kikuchi, H Yamashita, M Yoshida.   

Abstract

We measured soluble CD14 (sCD14), plasma endotoxin, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), IL-6, and interferon-gamma (IFN-gamma) in patients with multiple organ failure (MOF). The sCD14 level was significantly higher in septic patients with MOF than that in those without MOF and also higher in non-septic trauma patients with MOF than that in those without MOF. In the septic group with MOF, the sCD14 level correlated significantly with the TNF-alpha level but not the plasma endotoxin, IL-1 beta, IL-6, or IFN-gamma level. These results suggest that the sCD14 level reflects the degree of pathophysiology and that TNF-alpha is involved in stimulating sCD14 production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518965

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  3 in total

1.  Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.

Authors:  Serge Masson; Pietro Caironi; Caterina Fanizza; Ralf Thomae; Roberto Bernasconi; Andrea Noto; Roberto Oggioni; Giovanni Stefano Pasetti; Marilena Romero; Gianni Tognoni; Roberto Latini; Luciano Gattinoni
Journal:  Intensive Care Med       Date:  2014-10-16       Impact factor: 17.440

2.  Role of tumor necrosis factor alpha in induction of murine CD14 gene expression by lipopolysaccharide.

Authors:  C Fearns; D J Loskutoff
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

3.  Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia.

Authors:  Elham Olad; Iraj Sedighi; Azim Mehrvar; Maryam Tashvighi; Vahid Fallahazad; Amirabbas Hedayatiasl; Hossein Esfahani
Journal:  Iran J Pediatr       Date:  2014-11-28       Impact factor: 0.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.